ZLD Stock Overview
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia.
Zelira Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.88|
|52 Week High||AU$8.75|
|52 Week Low||AU$0.90|
|1 Month Change||29.66%|
|3 Month Change||44.62%|
|1 Year Change||-75.58%|
|3 Year Change||-86.23%|
|5 Year Change||-86.23%|
|Change since IPO||-53.29%|
Recent News & Updates
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ZLD||AU Pharmaceuticals||AU Market|
Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: ZLD underperformed the Australian Market which returned -7.9% over the past year.
|ZLD Average Weekly Movement||24.4%|
|Pharmaceuticals Industry Average Movement||11.4%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||17.5%|
|10% least volatile stocks in AU Market||4.7%|
Stable Share Price: ZLD is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.
Volatility Over Time: ZLD's weekly volatility has increased from 16% to 24% over the past year.
About the Company
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.
Zelira Therapeutics Fundamentals Summary
|ZLD fundamental statistics|
Is ZLD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZLD income statement (TTM)|
|Cost of Revenue||AU$862.50k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.07|
|Net Profit Margin||-785.91%|
How did ZLD perform over the long term?See historical performance and comparison
Is ZLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZLD?
Other financial metrics that can be useful for relative valuation.
|What is ZLD's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ZLD's PS Ratio compare to its peers?
|ZLD PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
EPN Epsilon Healthcare
ALA Arovella Therapeutics
ZLD Zelira Therapeutics
Price-To-Sales vs Peers: ZLD is expensive based on its Price-To-Sales Ratio (13.8x) compared to the peer average (13x).
Price to Earnings Ratio vs Industry
How does ZLD's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?
Price-To-Sales vs Industry: ZLD is expensive based on its Price-To-Sales Ratio (13.8x) compared to the Australian Pharmaceuticals industry average (9.1x)
Price to Sales Ratio vs Fair Ratio
What is ZLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||13.8x|
|Fair PS Ratio||17.6x|
Price-To-Sales vs Fair Ratio: ZLD is good value based on its Price-To-Sales Ratio (13.8x) compared to the estimated Fair Price-To-Sales Ratio (17.6x).
Share Price vs Fair Value
What is the Fair Price of ZLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ZLD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ZLD's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Zelira Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ZLD's forecast earnings growth is above the savings rate (1.8%).
Earnings vs Market: Insufficient data to determine if ZLD's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if ZLD's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ZLD's revenue (49.6% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: ZLD's revenue (49.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ZLD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Zelira Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZLD is currently unprofitable.
Growing Profit Margin: ZLD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.
Accelerating Growth: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).
Return on Equity
High ROE: ZLD has a negative Return on Equity (-26.09%), as it is currently unprofitable.
Discover strong past performing companies
How is Zelira Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ZLD's short term assets (A$9.0M) exceed its short term liabilities (A$935.6K).
Long Term Liabilities: ZLD's short term assets (A$9.0M) exceed its long term liabilities (A$416.2K).
Debt to Equity History and Analysis
Debt Level: ZLD is debt free.
Reducing Debt: ZLD has no debt compared to 5 years ago when its debt to equity ratio was 6.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZLD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ZLD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.6% each year
Discover healthy companies
What is Zelira Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZLD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZLD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ZLD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Oludare Odumosu serves as Director of Zelira Therapeutics Limited (formerly Zelda Therapeutics Ltd) since December 02, 2019. He serves as the Managing Director & Global Chief Executive Officer of Zelir...
CEO Compensation Analysis
Compensation vs Market: Oludare's total compensation ($USD385.78K) is above average for companies of similar size in the Australian market ($USD279.73K).
Compensation vs Earnings: Oludare's compensation has increased whilst the company is unprofitable.
Experienced Management: ZLD's management team is considered experienced (2.7 years average tenure).
Experienced Board: ZLD's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.8%.
Zelira Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Zelira Therapeutics Limited
- Ticker: ZLD
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$18.005m
- Shares outstanding: 9.58m
- Website: https://www.zeliratx.com
- Zelira Therapeutics Limited
- 101 St Georges Terrace
- Level 3
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.